Оксидантно-антиоксидантный профиль эндометрия: патогенез гиперпластических процессов

1. Management of endometrial intraepithelial neoplasia or atypical endometrial hyperplasia: ACOG Clinical Consensus No. 5. Obstet. Gynecol. 2023; 142(3): 735-44. https://dx.doi.org/10.1097/AOG.0000000000005297
2. Boureka E., Tsakiridis I., Kapetanios G., Michos G., Giouleka S., Liberis A. et al. Management of endometrial hyperplasia: a comparative review of guidelines. Cancers (Basel). 2025; 17(19): 3143. https://dx.doi.org/10.3390/cancers17193143
3. Doherty M.T., Sanni O.B., Coleman H.G., Cardwell C.R., McCluggage W.G., Quinn D. et al. Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: a systematic review and meta-analysis. PLoS One. 2020; 15(4): e0232231. https://dx.doi.org/10.1371/journal.pone.0232231
4. Chou A.J., Bing R.S., Ding D.C. Endometrial atypical hyperplasia and risk of endometrial cancer. Diagnostics (Basel). 2024; 14(22): 2471. https://dx.doi.org/10.3390/diagnostics14222471
5. Yıldırım E., Türkler C., Görkem Ü., Şimşek Ö.Y., Yılmaz E., Aladağ H. The relationship between oxidative stress markers and endometrial hyperplasia: a case-control study. Turk. J. Obstet. Gynecol. 2021; 18(4): 298-303. https://dx.doi.org/10.4274/tjod.galenos.2021.16132
6. Gentry-Maharaj A., Karpinskyj C. Current and future approaches to screening for endometrial cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 2020; 65: 79-97. https://dx.doi.org/10.1016/j.bpobgyn.2019.12.006
7. Ring K.L., Mills A.M., Modesitt S.C. Endometrial hyperplasia. Obstet. Gynecol. 2022; 140(6): 1061-75. https://dx.doi.org/10.1097/AOG.0000000000004989
8. Galani A., Stavros S., Moustakli E., Potiris A., Zikopoulos A., Anagnostaki I. et al. Endometrial hyperplasia: current insights into epidemiology, risk factors, and clinical management. Cancers (Basel). 2025; 18(1): 148. https://dx.doi.org/10.3390/cancers18010148
9. Niu S., Molberg K., Castrillon D.H., Lucas E., Chen H. Biomarkers in the diagnosis of endometrial precancers. Molecular characteristics, candidate immunohistochemical markers, and promising results of three-marker panel: current status and future directions. Cancers (Basel). 2024; 16(6): 1159. https://dx.doi.org/10.3390/cancers16061159
10. Bukato K., Kostrzewa T., Gammazza A.M., Gorska-Ponikowska M., Sawicki S. Endogenous estrogen metabolites as oxidative stress mediators and endometrial cancer biomarkers. Cell Commun. Signal. 2024; 22(1): 205. https://dx.doi.org/10.1186/s12964-024-01583-0
11. Lee J., Yeo S.G., Lee J.M., Kim S.S., Jeong Y.J., Oh T.I. et al. The role of reactive oxygen species in the pathogenesis and treatment of endometrial cancer. Front. Med. (Lausanne). 2025; 12: 1662794. https://dx.doi.org/10.3389/fmed.2025.1662794
12. Sies H. Oxidative eustress: the physiological role of oxidants. Sci. China Life Sci. 2023; 66(8): 1947-8. https://dx.doi.org/10.1007/s11427-023-2336-1
13. Sies H., Jones D.P. Reactive oxygen species as pleiotropic physiological signalling agents. Nat. Rev. Mol. Cell Biol. 2020; 21(7): 363-83. https://dx.doi.org/10.1038/s41580-020-0230-3
14. Halliwell B. Understanding mechanisms of antioxidant action in health and disease. Nat. Rev. Mol. Cell Biol. 2024; 25(1): 13-33. https://dx.doi.org/10.1038/s41580-023-00645-4
15. Sarmiento-Salinas F.L., Perez-Gonzalez A., Acosta-Casique A., Ix-Ballote A., Diaz A., Treviño S. et al. Reactive oxygen species: role in carcinogenesis, cancer cell signaling and tumor progression. Life Sci. 2021; 284: 119942. https://dx.doi.org/10.1016/j.lfs.2021.119942
16. Jomova K., Alomar S.Y., Alwasel S.H., Nepovimova E., Kuca K., Valko M. Several lines of antioxidant defense against oxidative stress. Arch. Toxicol. 2024; 98(5): 1323-67. https://dx.doi.org/10.1007/s00204-024-03696-4
17. Schieber M., Chandel N.S. ROS function in redox signaling and oxidative stress. Curr. Biol. 2014; 24(10): R453-62. https://dx.doi.org/10.1016/j.cub.2014.03.034
18. Averill-Bates D. Reactive oxygen species and cell signaling. Review. Biochim. Biophys. Acta Mol. Cell Res. 2024; 1871(2): 119573. https://dx.doi.org/10.1016/j.bbamcr.2023.119573
19. Zdrojkowski Ł., Jasiński T., Ferreira-Dias G., Pawliński B., Domino M. The role of NF-κB in endometrial diseases in humans and animals: a review. Int. J. Mol. Sci. 2023; 24(3): 2901. https://dx.doi.org/10.3390/ijms24032901
20. Huang L., Shi L., Li M., Yin X., Ji X. Oxidative stress in endometriosis: sources, mechanisms and therapeutic potential of antioxidants. Int. J. Mol. Med. 2025; 55(5): 1-11. https://doi.org/10.3892/ijmm.2025.5513
21. Drizi A., Djokovic D., Lagana A.S., Van Herendael B. Impaired inflammatory state of the endometrium: a multifaceted approach. Prz. Menopauzalny. 2020; 19(2): 90-100. https://dx.doi.org/10.5114/pm.2020.97863
22. AlAshqar A., Reschke L., Kirschen G.W., Borahay M.A. Role of inflammation in benign gynecologic disorders: from pathogenesis to novel therapies†. Biol. Reprod. 2021; 105(1): 7-31. https://dx.doi.org/10.1093/biolre/ioab054
23. Ruan L.Y., Lai Z.Z., Shi J.W., Yang H.L., Ye J.F., Xie F. et al. Excess heme promotes the migration and infiltration of macrophages in endometrial hyperplasia complicated with abnormal uterine bleeding. Biomolecules. 2022; 12(6): 849. https://dx.doi.org/10.3390/biom12060849
24. Moustakli E., Stavros S., Katopodis P., Skentou C., Potiris A., Panagopoulos P. et al. Oxidative stress and the NLRP3 inflammasome: focus on female fertility and reproductive health. Cells. 2025; 14(1): 36. https://dx.doi.org/10.3390/cells14010036
25. Krishna Kumar K., Upadhyaya K., Cn R.T. Bcl-2 may contribute to evolution of endometrial hyperplasia, but it isn't a factor in subsequent carcinogenesis. Arch. Razi Inst. 2024; 79(4): 827-32. https://dx.doi.org/10.32592/ARI.2024.79.4.827
26. Russo M., Newell J.M., Budurlean L., Houser K.R., Sheldon K., Kesterson J. et al. Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma. Cancer. 2020; 126(12): 2775-83. https://dx.doi.org/10.1002/cncr.32822
27. Aksakal S.E., Diktaş E.G., Pay R.E., Tapisiz Ö.L., Timur B., Korkmaz V. et al. The relationship between Thiol / disulfide homeostasis and endometrial hyperplasia in patients with abnormal uterine bleeding. Sağlık Akad. Kastamonu. 2022; 7(2): 340-51. https://dx.doi.org/10.25279/sak.1101029
28. Pejić S., Todorović A., Stojiljković V., Cvetković D., Lučić N., Radojičić R.M. et al. Superoxide dismutase and lipid hydroperoxides in blood and endometrial tissue of patients with benign, hyperplastic and malignant endometrium. An. Acad. Bras. Cienc. 2008; 80(3): 515-22. https://dx.doi.org/10.1590/S0001-37652008000300011
29. Шоонаева Н., Узакова А., Масыбаева А., Маматазизова А. Окислительный стресс при патологии эндометрия у женщин репродуктивного возраста. Репродуктивное здоровье. Восточная Европа. 2022; 12(5): 540-6.
30. Атыканов А.О., Асымбекова Г.У., Масыбаева А.А. Перекисное окисление липидов и система антиоксидантной защиты при гиперпластических процессах эндометрия у женщин. Ульяновский медико-биологический журнал. 2019; 4: 44-9.
31. Gómez-Zubeldia M.A., Bazo A.P., Gabarre J.J., Nogales A.G., Palomino J.C. Oxidative stress in endometrial hyperplasia. Menopause. 2008; 15(2): 363-8. https://dx.doi.org/10.1097/gme.0B013e318093E646
32. Błachnio-Zabielska A.U., Sadowska P., Zdrodowski M., Laudański P., Szamatowicz J., Kuźmicki M. The interplay between oxidative stress and sphingolipid metabolism in endometrial cancer. Int. J. Mol. Sci. 2024; 25(19): 10243. https:/dx./doi.org/10.3390/ijms251910243
33. Проскурнина Е.В., Фёдорова М.В., Вознесенский В.И., Соснова Е.А. Активность НАД(Ф)Н-оксидоредуктаз и оксидативный гомеостаз. Технологии живых систем. 2023; 20(4): 31-44.
34. Sezgin B., Pirinççi F., Camuzcuoğlu A., Erel Ö., Neşelioğlu S., Camuzcuoğlu H. Assessment of thiol disulfide balance in early-stage endometrial cancer. J. Obstet. Gynaecol. Res. 2020; 46(7): 1140-7. https://dx.doi.org/10.1111/jog.14301
35. Tossetta G., Marzioni D. Targeting the NRF2/KEAP1 pathway in cervical and endometrial cancers. Eur. J. Pharmacol. 2023; 941: 175503. https://dx.doi.org/10.1016/j.ejphar.2023.175503
36. Kuusiniemi E., Karihtala P., Puistola U., Ahtikoski A., Urpilainen E. Oxidative stress-regulating enzymes and endometrial cancer survival in relation to metformin intake in diabetic patients. Anticancer Res. 2023; 43(12): 5545-54. https://dx.doi.org/10.21873/anticanres.16756
37. Chen Y., Li Y., Huang L., Du Y., Gan F., Li Y. et al. Antioxidative stress: inhibiting reactive oxygen species production as a cause of radioresistance and chemoresistance. Oxid. Med. Cell. Longev. 2021; 2021: 6620306. https://dx.doi.org/10.1155/2021/6620306
38. Hu M., Sun D., Yu J., Fu Y., Qin Z., Huang B. et al. Brusatol sensitizes endometrial hyperplasia and cancer to progestin by suppressing NRF2-TET1-AKR1C1-mediated progestin metabolism. Lab. Invest. 2022; 102(12): 1335-45. https://dx.doi.org/10.1038/s41374-022-00816-5
39. Hayes J.D., Dinkova-Kostova A.T., Tew K.D. Oxidative stress in cancer. Cancer Cell. 2020; 38(2): 167-97. https://dx.doi.org/10.1016/j.ccell.2020.06.001
40. Žalytė E. Ferroptosis, metabolic rewiring, and endometrial cancer. Int. J. Mol. Sci. 2023; 25(1): 75. https://dx.doi.org/10.3390/ijms25010075
41. Zhou Q., Meng Y., Li D., Yao L., Le J., Liu Y. et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct. Target. Ther. 2024; 9(1): 55. https://dx.doi.org/10.1038/s41392-024-01769-5
42. Адамян Л.В., Пивазян Л.Г., Курбатова К.С., Маилова К.С., Степанян А.А. Оксидативный стресс, ферроптоз, соматические мутации, антиоксидантная терапия и эндометриоз: новый взгляд на проблему. Проблемы репродукции. 2024; 30(6): 32-44.
43. Yu Q., Ren L., Ren F., Li F. Integrating mitophagy and ferroptosis in endometrial carcinogenesis (Review). Oncol. Lett. 2025; 31(1): 40. https://dx.doi.org/10.3892/ol.2025.15393
44. Murakami H., Hayashi M., Terada S., Ohmichi M. Medroxyprogesterone acetate-resistant endometrial cancer cells are susceptible to ferroptosis inducers. Life Sci. 2023; 325: 121753. https://dx.doi.org/10.1016/j.lfs.2023.121753
45. Qiang B., Kang Y.F., Yang J.L., Su H.C., Wang Z., Zhang C.M. et al. Prognostic value of VEGF in endometrial cancer. Medicine (Baltimore). 2024; 103: e40933. https://dx.doi.org/10.1097/MD.0000000000040933
46. Aggarwal V., Tuli H.S., Varol A., Thakral F., Yerer M.B., Sak K. et al. Role of reactive oxygen species in cancer progression: molecular mechanisms and recent advancements. Biomolecules. 2019; 9(11): 735. https://dx.doi.org/10.3390/biom9110735
47. Madeddu C., Sanna E., Gramignano G., Tanca L., Cherchi M.C., Mola B. et al. Correlation of leptin, proinflammatory cytokines and oxidative stress with tumor size and disease stage of endometrioid (Type I) endometrial cancer and review of the underlying mechanisms. Cancers (Basel). 2022; 14(2): 268. https://dx.doi.org/10.3390/cancers14020268
48. Yan J., Ye G., Shao Y. High expression of the ferroptosis‐associated MGST1 gene in relation to poor outcome and maladjusted immune cell infiltration in uterine corpus endometrial carcinoma. J. Clin. Lab. Anal. 2022; 36(4): e24317. https://dx.doi.org/10.1002/jcla.24317

Поступила 28.01.2026

Принята в печать 11.02.2026